The Stop STALLING Act gives the Federal Trade Commission a statutory remedy against so‑called "sham" citizen petitions submitted under FDA authority to obstruct approval of competing generic drugs or biosimilars. It defines covered petitions and sham conduct, allows the FTC to bring civil suits in federal court, and authorizes civil penalties for violations.
The bill creates a streamlined pathway for enforcement by treating an HHS determination that a petition’s primary purpose was to delay approval and a written referral to the FTC as triggering a presumption that a related series of petitions is a sham — subject to a defendant’s rebuttal. Penalties are calibrated either to revenue tied to the referenced drug or to a daily fine (up to $50,000 per day), and remedies stack with other federal antitrust authorities.
At a Glance
What It Does
Authorizes the FTC to sue in federal court anyone who submits or causes submission of a covered citizen petition (or series of such petitions) that is a sham, treating such conduct as an unfair method of competition under section 5(a)(1) of the FTC Act. The statute defines a sham as either an objectively baseless petition aimed at using a government process to interfere with a competitor or a series of petitions deployed for that purpose.
Who It Affects
Brand pharmaceutical firms, their outside counsel and affiliates that use citizen petitions to delay competitors; generic and biosimilar applicants awaiting FDA or HHS review; the FTC and HHS/FDA because of new inter‑agency referral mechanics and enforcement workload. Legal teams that regularly file FDA petitions will need new litigation and compliance assessments.
Why It Matters
The measure converts certain citizen‑petition activity into an enforcement exposure with substantial monetary risk and a presumption mechanism built on HHS findings. That changes the calculus for companies using regulatory petitions as competitive tools and signals a stronger federal stance linking regulatory process abuse to antitrust enforcement.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill focuses narrowly on petitions filed under the FDA citizen‑petition provision that relate to pending applications for generic drugs (505(b)(2) or 505(j)) and biosimilars (351(k)). It starts by defining key terms: what counts as a covered application and covered petition; who counts as a person (including successors, affiliates, and controlled entities); what a ‘‘series’’ of petitions is; and what a ‘‘sham’’ petition looks like.
The definition of sham covers individually baseless petitions and repeated filings intended to weaponize the regulatory process rather than to obtain a regulatory outcome.
On substance, the Act makes submission of a sham petition an unfair method of competition under section 5(a)(1) of the FTC Act and gives the FTC authority to bring civil suits in federal district court to recover penalties and other relief. If HHS determines a petition’s primary purpose was delay and refers that finding to the FTC with a reasoned basis, the statute creates a rebuttable presumption that the petition is part of a sham series — provided the petition is indeed one of multiple related filings.
Defendants can overcome that presumption by a preponderance of the evidence.Penalty design is consequential. For each violation the FTC proves, the bill allows a civil penalty equal to the greater of (1) revenue earned by the alleged wrongdoer from sales of the referenced drug during the review period or (2) $50,000 for each calendar day the sham petition (or each petition in the sham series) was under HHS review.
The bill makes clear these penalties are cumulative with other remedies under the antitrust laws and existing FTC authorities.Implementation touches interagency procedure and judicial review. HHS referrals are not independently reviewable except as a third‑party APA claim the defendant can assert against HHS in the FTC action.
The Act applies only to petitions submitted on or after enactment, preserves other FTC powers, and includes a severability clause so remaining provisions survive if one part is struck down.
The Five Things You Need to Know
The statutory presumption that a petition is part of a sham series kicks in only after HHS determines the petition’s primary purpose was delaying approval and sends a written, reasoned referral to the FTC.
A defendant can rebut the presumption, but must do so by a preponderance of the evidence in the FTC’s civil action.
Civil penalties are calculated per violation as the greater of: revenue from sales of the referenced drug during the petition review period, or $50,000 for each calendar day the sham petition (or each petition in the sham series) remained under HHS review.
The bill’s definition of person expressly sweeps in successors, assigns, controlled affiliates, joint ventures, and similar corporate configurations, widening who can be held liable.
HHS referral determinations are largely insulated from standalone judicial review; they can only be challenged by the defendant as a third‑party APA claim brought inside the FTC enforcement case.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the Act the "Stop Significant and Time‑wasting Abuse Limiting Legitimate Innovation of New Generics Act" or the "Stop STALLING Act." This is procedural but signals the stated purpose: to target abuse of the citizen‑petition route that delays generic and biosimilar entry.
Who, what, and when: covered petitions and sham conduct
Sets precise scope: covered applications are specified FDA pathways (505(b)(2), 505(j), and 351(k)); covered petitions are those filed under FDA’s 505(q) citizen‑petition authority. The statute defines a series as more than one petition relating to the same covered application and defines 'sham' both for single petitions that are objectively baseless and for series of petitions used to weaponize the process. Importantly, the term 'person' tracks broadly to capture corporate structures and successors, which matters for enforcement against parent companies, affiliates, and entities that acquire assets.
Converts sham petitions into an FTC violation
Declares that submitting (or causing submission of) a covered petition or series of petitions that is a sham constitutes an unfair method of competition under section 5(a)(1) of the FTC Act. That hooks the conduct to the FTC’s general unfair competition authority rather than to a new standalone cause of action, giving the agency a familiar statutory home but expanding exposure for petition filers.
FTC civil suits, HHS referrals, presumption, penalties, and limits on review
Authorizes the FTC to commence civil actions in federal court when it has reason to believe a covered petition is a sham. The provision creates a rebuttable presumption that a petition belongs to a sham series if HHS has found the primary purpose was delay and has provided a written referral with reasoning, and the petition was part of a series. The defendant may rebut by preponderance. Penalties are significant: for each violation the FTC proves, the liable party faces the greater of revenue tied to the referenced drug during review or $50,000 per calendar day the petition was under review. The section preserves antitrust statutes’ applicability, clarifies penalties are in addition to other remedies, and restricts direct judicial review of HHS referrals except as a third‑party APA challenge in the FTC action.
Effective date for covered petitions
States the statute applies to covered petitions submitted on or after the Act’s enactment date. That limits retroactivity and signals that already‑pending petitions are not retroactively subject to these new penalties or presumption mechanics.
Preserves other FTC authorities
Clarifies nothing in the Act narrows the FTC's existing powers under any other law. Practically, the agency can pursue sham petitions under this new pathway while still invoking traditional FTC tools and antitrust statutes where appropriate.
Survival of remaining provisions
Provides that if any provision is found unconstitutional or otherwise invalid in a particular application, the rest of the Act remains effective. This is a standard structural provision intended to protect the statute from total invalidation if one piece is struck down.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Generic and biosimilar manufacturers awaiting approval — faster and less obstructed FDA review cycles reduce time‑to‑market and commercial uncertainty when petition abuse declines.
- Patients and payers (insurers, Medicare) — reduced successful delays of lower‑cost competition can lower drug prices and improve access once generics/biosimilars reach the market sooner.
- FTC enforcement priorities — the agency gains a tailored, statutory enforcement lever against regulatory process abuse, making it easier to bring actions targeting delay strategies backed by evidence and HHS referrals.
Who Bears the Cost
- Brand‑name pharmaceutical companies and affiliates that use citizen petitions strategically — increased litigation risk, potential for large revenue‑based penalties, and need to retool regulatory strategy and outside counsel relationships.
- Outside law firms and consultancies that prepare and file citizen petitions — potential malpractice or liability exposure if filings are later deemed sham and increased due diligence costs to document good‑faith bases.
- HHS/FDA — added administrative burden to investigate motives, prepare reasoned referrals that trigger the statutory presumption, and coordinate with the FTC; documenting a 'primary purpose' finding could require resources and new internal processes.
Key Issues
The Core Tension
The central dilemma is striking a balance between deterring strategic, anticompetitive uses of the FDA petition process and preserving robust channels for legitimate safety and public‑health concerns; the bill tips enforcement power toward the FTC and elevates HHS referrals as a trigger, which improves deterrence but risks chilling lawful petitions and shifting significant proof‑and‑administrative burdens onto agencies and regulated parties.
The Act confronts a real problem — tactical petitions that delay competition — but it raises hard implementation questions. First, proving intent or primary purpose to delay typically rests on circumstantial evidence; the statute relies heavily on HHS factual findings to create a presumption, but HHS may lack clear standards or capacity to make consistent determinations.
Second, the monetary remedy structure (revenue‑based or $50,000/day) could produce very large damages tied to sales calculations that are complex to work through: which revenue streams count, over what period, and how to apportion revenue where products are combined or sold by affiliates.
A second set of trade‑offs concerns chill versus deterrence. The Act risks deterring meritorious safety or policy petitions that raise genuine public‑health issues but also slow competitors — especially where companies fear treble‑like commercial exposure or protracted FTC litigation.
Finally, limiting standalone judicial review of HHS referrals narrows early court intervention; defendants retain only a third‑party APA vehicle inside the FTC action, which could complicate timely adjudication of agency errors or politically motivated referrals. Coordination with existing antitrust law is preserved, but overlapping doctrines (abuse of process, sham litigation, antitrust tying) create potential for duplicative or inconsistent litigation strategies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.